The resting heart rate (RHR), often referred to as cardiac frequency at rest, is perhaps one of the most accessible and clinically informative measures that can be taken. Convincing evidence has emerged that increased RHR may significantly predict the risk of death, especially in patients with cardiovascular disease (CVD). The crucial questions that emerge here and now, irrespective of an active or passive role played by atherosclerosis biomarkers in modulating atherogenesis, are (1) whether their assessment may be worth — more specifically cost-effective — in baseline estimation of the CVD risk and (2) whether specific therapeutic interventions shall be planned for targeting their eventually increased concentration in plasma. Further evidence would be needed before this intriguing link can have an effective translation into routine clinical practice.
Atherosclerosis biomarkers and resting heart rate: active players or simple bystanders?
Giuseppe Lippi
;
2022-01-01
Abstract
The resting heart rate (RHR), often referred to as cardiac frequency at rest, is perhaps one of the most accessible and clinically informative measures that can be taken. Convincing evidence has emerged that increased RHR may significantly predict the risk of death, especially in patients with cardiovascular disease (CVD). The crucial questions that emerge here and now, irrespective of an active or passive role played by atherosclerosis biomarkers in modulating atherogenesis, are (1) whether their assessment may be worth — more specifically cost-effective — in baseline estimation of the CVD risk and (2) whether specific therapeutic interventions shall be planned for targeting their eventually increased concentration in plasma. Further evidence would be needed before this intriguing link can have an effective translation into routine clinical practice.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
